Concomitant inhibition of Janus kinase 3 and calcineurin-dependent signaling pathways synergistically prolongs the survival of rat heart allografts

Journal of Immunology

Volumn 166, Issue 6, 2001, Pages 3724-3732

  Behbod, F ^a   Erwin Cohen, R A ^a   Wang, M E ^a   Trawick, B W ^a   Qu, X ^a   Verani, R ^a   Kahan, B D ^a   Stepkowski, S M ^a   Kirken, R A ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN; CYCLOSPORIN A; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 7; JANUS KINASE; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; RAPAMYCIN; STAT5 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHOSPHORYLATION; CELL INFILTRATION; CELL PROLIFERATION; COMBINED IMMUNODEFICIENCY; CONTROLLED STUDY; DNA BINDING; DRUG POTENTIATION; ENZYME INHIBITION; ENZYME LOCALIZATION; GENE INACTIVATION; GRAFT SURVIVAL; HEART TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; MONONUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION;

EID: 0035869505     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.166.6.3724     Document Type: Article

References (70)

1. Immunosuppressive strategies in transplantation
2. Two paradigms for new immunosuppressive strategies in organ transplantation
3. Signal transduction by lymphocyte antigen receptors
4. Signal transduction by the TCR for antigen
5. Mammalian target of rapamycin: Immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling
6. Sirolimus (Rapamune, rapamycin) is more effective than azathioprine to reduce the incidence of acute renal allograft rejection episodes when used in combination with cyclosporine and prednisone: A phase III U.S. multicenter trial
7. Effects of the pharmacokinetic interaction between orally administered sirolimus and cyclosporine on the synergistic prolongation of heart allograft survival in rats
8. Sharing of the interleukin-2 (IL-2) receptor γ chain between receptors for IL-2 and IL-4
9. Interleukin-2 receptor γ chain: A functional component of the interleukin-7 receptor
10. Interleukin-2 receptor γ chain: A functional component of the interleukin-4 receptor
11. Interaction of IL-2Rβ and γc chains with Jak1 and Jak3: Implications for XSCID and XCID
12. Activation of JAK3, but not JAK1, is critical for IL-2-induced proliferation and STATS recruitment by a COOH-terminal region of the IL-2 receptor β-chain
13. IL-2 and IL-4 double knockout mice reject islet allografts: A role for novel T cell growth factors in allograft rejection
14. IL-2 knockout recipient mice reject islet cell allografts
15. Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting
16. Interleukin-2 receptor α chain regulates the size and content of the peripheral lymphoid compartment
17. Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor β
18. Utilization of the β and γ chains of the IL-2 receptor by the novel cytokine IL-15
19. Interleukin 2 and its receptors: Recent advances and new immunological functions
20. Peripheral expression of Jak3 is required to maintain T lymphocyte function
21. T cells from Jak3-deficient mice have intact TCR signaling, but increased apoptosis
22. STATs and gene regulation
23. Star5 is required for IL-2-induced cell cycle progression of peripheral T cells
24. Star5 activation is uniquely associated with cytokine signaling in peripheral T cells
25. Correction of interleukin-2 receptor function in X-SCID lymphoblastoid cells by retrovirally mediated transfer of the γ-c gene
26. In vitro correction of JAK3-deficient severe combined immunodeficiency by retroviral mediated gene transduction
27. Blocking the common γ-chain of cytokine receptors induces T cell apoptosis and long-term islet allograft survival
28. Antisense oligonucleotides targeted to the p53 gene modulate liver regeneration in vivo
29. Tyrosine kinase inhibition: An approach to drug development
30. Tyrphostin AG-490 inhibits cytokine-mediated JAK3/STAT5a/b signal transduction and cellular proliferation of antigen-activated human T cells
31. JAK3, STAT, and MAPK signaling pathways as novel molecular targets for the tyrphostin AG-490 regulation of IL-2-mediated T cell response
32. Inhibition of acute lymphoblastic leukemia by a Jak-2 inhibitor
33. Differential control of the phosphorylation state of proline-juxtaposed serine residues Ser725 of Stat5a and Ser730 of Stat5b in prolactin-sensitive cells
34. Improved technique of heart transplantation in rats
35. Models of inflammatory cascade reactions by adhesion molecules
36. Cytokine mRNA expression in tolerant heart allogrfts after immunosuppression with cyclosporine, sirolimus, or brequinar
37. The median effect principle and the combination index for quantitation of synergism and antagonism
38. Receptor-mediated mitogenic action of prolactin in a rat lymphoma cell line
39. Signaling via IL-2 and IL-4 in JAK3-deficient severe combined immunodeficiency lymphocytes: JAK3-dependent and independent pathways
40. Dispensability of Jak1 tyrosine kinase for interleukin-2-induced cell growth signaling in a human T cell line
41. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation
42. Requirement of serine phosphorylation for formation of STAT-promoter complexes
43. Ser727-dependent recruitment of MCM5 by Stat1α in IFN-γ-induced transcriptional activation
44. Prolactin stimulates serine/tyrosine phosphorylation and formation of heterocomplexes of multiple STAT5 isoforms in Nb2 lymphocytes
45. Two discrete regions of interleukin-2 (IL2) receptor β independently mediate IL2 activation of a PD98059/rapamycin/wortmannin-insensitive Stat5a/b serine kinase
46. Lessons from immunological, biochemical, and molecular pathways of the activation mediated by IL-2 and IL-4
47. Restoration of lymphocyte function in Janus kinase 3-deficient mice by retroviral-mediated gene transfer
48. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease
49. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway
50. Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells
51. Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene
52. Immunocompromised tumor-bearing mice show a selective loss of STAT5a/b expression in T and B lymphocytes
53. HIV-1 infection induces a selective reduction in STAT5 protein expression
54. Clonal anergy is induced in vitro by T cell receptor occupancy in the absence of proliferation
55. Analysis of intragraft effector mechanisms associated with human renal allograft rejection: Immunohistological studies with monoclonal antibodies
56. Inhibition of experimental autoimmune encephalomyelitis by a tyrosine kinase inhibitor
57. Jak2 is essential for signaling through a variety of cytokine receptors
58. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo
59. Blocking both signal I and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance
60. Reversal of in vitro T cell clonal anergy by IL-2 stimulation
61. Inhibition of cell cycle progression by rapamycin induces T cell clonal anergy even in the presence of costimulation
62. A signaling pathway to translational control
63. Ribosomal protein S6 phosporylation and signal transduction
64. Molecular cloning and characterization of a novel p70 S6 kinase, p70 S6 kinase β containing a proline-rich region
65. s6k gene reveals a small mouse phenotype and a new functional S6 kinase
66. Regulation of translation elongation factor-2 by insulin via a rapamycin-sensitive signalling pathway
67. eLF4 initiation factors: Effectors of mRNA recruitment to ribosomes and regulators on translation
68. Serum-stimulated, rapamycin-sensitive phosphorylation sites in the eukaryotic translation initiation factor 4G1
69. Synergistic mechanisms by which sirolimus and cyclosporine inhibit rat heart and kidney allograft rejection